
Moscow Hosts IFPMA's Biosimilars Conference
Representatives of national health regulatory authorities from around the world convened in Moscow to discuss ways to harmonize regulatory standards for biotherapeutic medicines.
Representatives of national health regulatory authorities from around the world convened in Moscow to discuss ways to harmonize regulatory standards for biotherapeutic medicines.
The conference, Biotherapeutic medicines: regulatory challenges and current practices - approaches for harmonization, was the first international expert meeting of its kind to take place in Russia. Participating in the conference were experts from Russia, Belarus, Kazakhstan, Ukraine, the World Health Organization, Health Canada, several European national regulatory agencies, and industry. Participants were scheduled to discuss current challenges in regulating biotherapeutic and biosimilar medicines and exchange best practices.
The conference was organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in cooperation with the Association of International Pharmaceutical Manufacturers (AIPM). It is held with the support and participation of the Ministry of Health of the Russian Federation, the Russian Federal Service for Healthcare Supervision, the Eurasian Economic Commission, the State Duma Committee on Health Protection, and the Russian Academy of Medical Sciences.
Ahead of the conference, AIPM Executive Director Vladimir Shipkov said
IFPMA Director General Eduardo Pisani said, "Biotherapeutic medicines open new possibilities for medicines and offer cures for some diseases that were previously considered untreatable. With more than 200 biotherapeutic medicines now registered and many others in the pipeline, science-based, harmonized regulatory approaches are needed. This conference is an important platform for sharing regulatory best practices among leading Russian and international experts."
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.